Zinc Therapy for Acrodermatitis Enteropathica

Dosing Recommendations

• Prescribe oral elemental zinc at 3 mg per kilogram of body weight per day for patients with hereditary acrodermatitis enteropathica, with lifelong continuation and dose titration guided by plasma zinc concentrations. 1
• For acquired zinc‑deficiency states (e.g., malnutrition, parenteral nutrition without zinc, malabsorption), use 0.5–1 mg/kg/day for a limited course of 3–4 months, after which therapy is discontinued. 1

Formulation Preference

• Choose organic zinc salts (zinc gluconate, zinc histidinate, or zinc orotate) because they are better tolerated than inorganic salts such as zinc sulfate or zinc chloride. 1

Guideline Consensus (ESPEN)

• The European Society for Clinical Nutrition and Metabolism (ESPEN) 2022 micronutrient guidelines assign a Grade 0 recommendation with 94 % strong consensus to the 3 mg/kg/day lifelong dosing regimen for hereditary acrodermatitis enteropathica. 1

Monitoring and Dose Adjustment

• Plasma zinc levels should be measured regularly to adjust the dose and maintain therapeutic concentrations. 1
• When assessing zinc status, simultaneously measure C‑reactive protein (CRP) and albumin; an elevated CRP > 20 mg/L markedly lowers plasma zinc and can confound interpretation. 3

Toxicity Prevention

• Do not exceed the recommended zinc intake; acute toxicity (nausea, vomiting) typically occurs when ingestion surpasses 1–2 g per day. 1, 3
• Chronic zinc excess may induce copper deficiency; treatment involves supplementation with copper sulfate. 1

Follow‑up and Practical Prescribing

• Calculate the daily elemental zinc dose as 3 mg per kilogram of body weight (e.g., a child weighing 10 kg receives 30 mg elemental zinc daily). 1
• After initiating therapy, re‑check plasma zinc after 1–2 months, then schedule monitoring every 6–12 months to ensure continued adequacy and detect potential toxicity. 1